Fact based stock research
Astellas Institute for Regenerative Medicine ()




Research on Ocata Therapeutics, Inc. has been discontinued due to the acquisition by Astellas US Holding, Inc. .



Astellas Institute for Regenerative Medicine stock research in summary


Astellas Institute for Regenerative Medicine stock research analysis by the purely financial fact-based Obermatt method on current and historical performance by investment strategy | Astellas Institute for Regenerative Medicine, Biotechnology, USA


Latest Obermatt Ranks


Country USA
Industry Biotechnology
Index
Size class X-Small

January 22, 2016. Stock data may be delayed. Login to get the most recent research.


Research History: Astellas Institute for Regenerative Medicine

RESEARCH HISTORY 2016 2017 2018 2019
VALUE
VALUE
GROWTH
GROWTH
SAFETY
SAFETY
COMBINED
COMBINED

Last update of Combined Rank: 22-Jan-2016. Financial reporting date used for calculating ranks: 30-Sep-2015. Stock research history is based on the Obermatt Method. The higher the rank, the better Astellas Institute for Regenerative Medicine is in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2016 2017 2018 2019
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)
DIVIDEND YIELD
DIVIDEND YIELD
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE

Last update of Value Rank: 22-Jan-2016. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Astellas Institute for Regenerative Medicine; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2016 2017 2018 2019
REVENUE GROWTH
REVENUE GROWTH
PROFIT GROWTH
PROFIT GROWTH
STOCK RETURNS
STOCK RETURNS
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH

Last update of Growth Rank: 30-Sep-2015. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Astellas Institute for Regenerative Medicine.


Safety Metrics in Detail

SAFETY METRICS 2016 2017 2018 2019
LEVERAGE
LEVERAGE
REFINANCING
REFINANCING
LIQUIDITY
LIQUIDITY
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY

Last update of Safety Rank: 18-Jan-2016. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Astellas Institute for Regenerative Medicine and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Astellas Institute for Regenerative Medicine from January 22, 2016.


We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.

Register for
stock tips now


Stock investing made easy